Business Description
Vanda Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US9216591084
Share Class Description:
VNDA: Ordinary SharesTotal Employee Number:
533Description
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.45 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.13 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -1.27 | |||||
Beneish M-Score | -4.24 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -6.3 | |||||
3-Year Book Growth Rate | -15.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 56.14 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 22.94 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.42 | |||||
9-Day RSI | 64.59 | |||||
14-Day RSI | 56.49 | |||||
3-1 Month Momentum % | -9.18 | |||||
6-1 Month Momentum % | -10.82 | |||||
12-1 Month Momentum % | 20.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.61 | |||||
Quick Ratio | 1.6 | |||||
Cash Ratio | 1.04 | |||||
Days Inventory | 51.02 | |||||
Days Sales Outstanding | 90.25 | |||||
Days Payable | 126.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.3 | |||||
Shareholder Yield % | -1.17 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.74 | |||||
Operating Margin % | -86.07 | |||||
Net Margin % | -127.41 | |||||
EBITDA Margin % | -79.19 | |||||
FCF Margin % | -70.93 | |||||
OCF Margin % | -65.98 | |||||
ROE % | -77.19 | |||||
ROA % | -53.66 | |||||
ROIC % | -69.26 | |||||
3-Year ROIIC % | -240.11 | |||||
ROC (Joel Greenblatt) % | -1223.22 | |||||
ROCE % | -49.47 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 23.51 | |||||
PS Ratio | 1.47 | |||||
PB Ratio | 1.48 | |||||
Price-to-Tangible-Book | 3.04 | |||||
EV-to-EBIT | -0.96 | |||||
EV-to-EBITDA | -1.04 | |||||
EV-to-Forward-EBITDA | 15.37 | |||||
EV-to-Revenue | 0.83 | |||||
EV-to-Forward-Revenue | 0.79 | |||||
EV-to-FCF | -1.16 | |||||
Price-to-GF-Value | 0.99 | |||||
Price-to-Projected-FCF | 3.82 | |||||
Price-to-Median-PS-Value | 0.56 | |||||
| Price-to-Net-Current-Asset-Value | 4.52 | |||||
Earnings Yield (Greenblatt) % | -104.17 | |||||
FCF Yield % | -47.04 | |||||
Forward Rate of Return (Yacktman) % | -4.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VNDA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vanda Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 215.721 | ||
| EPS (TTM) ($) | -4.63 | ||
| Beta | 0.5373 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.17 | ||
| Volatility % | 82.89 | ||
| 14-Day RSI | 56.49 | ||
| 14-Day ATR ($) | 0.261488 | ||
| 20-Day SMA ($) | 5.18425 | ||
| 12-1 Month Momentum % | 20.09 | ||
| 52-Week Range ($) | 4.27 - 9.94 | ||
| Shares Outstanding (Mil) | 60.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vanda Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vanda Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-12 | In 176 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-11 16:30 | In 176 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-11 | In 175 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 16:30 | In 71 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 70 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 5.33 (+1.72%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 5.33 (+1.72%) | ||
| General meeting for 2026 | 2026-06-04 09:00 | 6.09 (-1.14%) | ||
| Guidance call for 2026 | 2026-05-20 | 5.99 (-1.48%) | ||
| HCW 4th Annual BioConnect Investor Conference | 2026-05-19 14:00 | 6.08 (-4.70%) |
Show
Entries
Vanda Pharmaceuticals Inc Frequently Asked Questions
What is Vanda Pharmaceuticals Inc(VNDA)'s stock price today?
The current price of VNDA is $5.38. The 52 week high of VNDA is $9.94 and 52 week low is $4.27.
When is next earnings date of Vanda Pharmaceuticals Inc(VNDA)?
The next earnings date of Vanda Pharmaceuticals Inc(VNDA) is 2026-10-29 Est..
Does Vanda Pharmaceuticals Inc(VNDA) pay dividends? If so, how much?
Vanda Pharmaceuticals Inc(VNDA) does not pay dividend.
Guru Commentaries on NAS:VNDA
No articles.
Press Release
Articles on Vanda Pharmaceuticals Inc
Is Vanda Pharmaceuticals (VNDA) Facing Growth Challenges After Q2 Earnings? GF Score: 76/100
Aug 05, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers